Travere Therapeutics (TVTX) Tops Q1 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. NVDA
2. PCVX
3. PTC
4. MSFT
5. SPY
6. META
7. GMAB
8. AMD
9. BBIO
10. USO

Go back to Travere Therapeutics (TVTX) Tops Q1 EPS by 3c

Travere Therapeutics Reports First Quarter 2022 Financial Results

May 5, 2022 4:01 PM EDT

Submitted New Drug Application (NDA) for sparsentan in IgA nephropathy in March 2022

Results from Phase 1/2 COMPOSE Study of pegtibatinase in classical homocystinuria (HCU) presented at the Society for Inherited Metabolic Disorders (SIMD) 43rd Annual Meeting

Refinanced $207 million of 2025 convertible notes through offering of $316 million convertible senior notes due 2029

SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its first quarter 2022 financial results and provided a corporate update.

... More